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Alexander disease (AxD) primarily affects the white matter of the central 
nervous system (CNS). It is an astrogliopathy in which Astroglial cells 
involved in maintenance homeostasis and providing defence to the brain are 
affected. Therefore their dysfunction has been implicated in a number of 
neurological, neuropsychiatric and neurodegerative disorders. GFAP (Glial 
fibrillary acidic protein) is the major intermediate filament protein present in 
astrocytes whose heterozygous missense mutations have been reported to be a 
cause of AxD. In the absence of any effective therapeutic intervention of AxD, 
in the present study PTGS (Post transcriptional gene silencing) approach to 
knock down mutant gfap gene. Various mutations causing AxD were checked 
for their pathogenicity using various in silico tools and 13 mutations were 
shortlisted based on their pathogenicity and probability of occurrence. 
Thereafter siRNA were designed against the mutant genes to silence them and 
thereby preventing the accumulation of mutant gfap that causes the 
pathophysiology of AxD.  
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A large amount of data is being generated, due to advancement in "omics", therefore systems biology 
aims to condense and analyze their molecular data to draw meaningful perceptions from it. As large amount of 
data is being generated, computational biology through pragmatic modeling and theoretical exploration 
provides a robust foundation to formulate and solve crucial biological issues [1]. There has been large amount of 
progress in research related to human genetics and genomics since the publication of human genome sequence 
draft. These studies have led to special discoveries within the context of transmitted genetic variations [2] and 
somatic mutations in cancer genomes [3]. Advances in genomics have triggered a revolution in discovery-based 
analysis to grasp even the foremost complicated biological systems like the brain [4].  
There has been a surge in discovery of variants due to genetic testing becoming more widely available. 
The method of classifying the unknown variances into pathogenic or neutral have been dashed up with the 
development of in silico programs [5]. Missense mutations are usually benign while nonsense and frameshift 
mutations, that cause premature termination of protein production, have been reported to be pathogenic. The 
discovery and interpretation of single nucleotide variants (SNVs) is cumbersome, at the same time resulting in 
novel discoveries [6]. Missense mutations are a type of nonsynonymous substitution found in DNA [7] and have 
been reported to cause human diseases such as Epidermolysisbullosa, sickle-cell disease, 
and SOD1 mediated Amyotrophic lateral sclerosis (ALS) since they result in the formation of non-functional 
proteins [8].  
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The activity of specifically target genes can be altered/terminated using the technique of gene silencing 
which is based on a natural process that is used to degrade mRNA transcribed from a specific gene, thereby 
preventing expression of gene and synthesis of corresponding protein. Therefore to silence gene expression Post 
Transcriptional Gene Silencing (PTGS) has been used to cause effective and specific inhibition of disease-
causing genes [9]. siRNA molecules based therapy has been successfully used to target a number of mutant 
genes such as SOD1 associated with ALS [10], viral gene expression in cancerous cells, knockdown of host 
receptors and coreceptors for HIV [11], silencing of hepatitis A [12], hepatitis B genes [13], influenza gene 
expression [14], and measles viral replication [15]. ‘Genetic medicines’ have been developed for the treatment 
of nearly 1,800 known monogenic hereditary disorders [15]. PTGS has also been used to treat asthma and 
metabolic diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis [16]. It has also 
been reported that bacterial diseases can be prevented by targeting the host genes involved in the immune 
response caused by infection or those that mediate entry of bacteria into host cells [17-18].  
Alexander disease (AxD) is a very rare, progressive and fatal neurological disorder that was first 
described by WS Alexander in 1949 characterized by genetic disorder of astrocytes that mainly affects young 
children [19]. The pathophysiology of the disease is decreased myelin formation, which is the fatty, insulating 
wrapping sheath around nerve fibers and constitutes the white matter of brain. Therefore AxD has been included 
among leukodystrophies [20].  
The characteristic feature of AxD is the accumulation of abnormal protein aggregates of glial fibrillary 
acidic protein (GFAP) in astrocytes which are referred as “Rosenthal fibers” dispersed in the brain and spinal 
cord [21]. AxD has been reported to be caused due to heterozygous, sporadic and missense mutations in gfap 
that codes for GFAP present on chromosome 17q21 [22]. Brenner et al. (2001) performed sequence analysis of 
DNA from patients representing different AxD phenotypes, reported that most cases were associated with 
nonconservative mutations in the coding region of the gfap gene [23] and nearly one-third involve either of two 
amino acids- ARG79 or ARG239 [24]. ARG79 and ARG239 (R79 and R239) positions hot spots have produced 
the greatest variety of substitutions: C, H, L, G and S for ARG79 (R79) (only P is missing among possible 
single nucleotide mutations), and C, H, L and P for ARG239 (R239) (only G and S are missing). Arginine 
codons are recognized as particularly prone to mutation, presumably due to methylation of the CpG dinucleotide 
[25].  
For the treatment of AxD the current standard focuses on control of seizure, nutrition, and maintenance 
of pulmonary function. Only three reports describe attempts at alternative forms of therapy such as bone marrow 
transplantation which was given to one patient who died after 4.5 months at the age of 1 year [26]. Due to 
absence of any specific therapeutic intervention of Alexander Disease, the present study was undertaken to 
target the disease at genetic level by designing siRNAs to knock down the mutant gfap gene thereby preventing 




2. RESEARCH METHOD 
2.1  Sequence Retrieval: 
 The nucleotide sequence for gfap gene (Homo sapiens) was retrieved from NCBI (Accession No. - 
NM_002055). 
 
2.2 Mutation Analysis 
2.2.1 Databases   
The variations reported to cause AxD were collected from the database OMIM. 
 
2.2.2 Prediction of pathogenic mutations   
To check the pathogenicity of these reported variations in the GFAP protein, they were analyzed using 
in silico mutation analysis tools to predict their damaging effect on the protein function. 
 
2.2.2.1 UMD Predictor (Universal Mutation Database Predictor) 
UMD predictor was used for assessment of pathogenic missense and synonymous mutations and 
follows a combinatorial approach. The algorithm score ranges from 0 to 100 and is divided into four classes -
<50 polymorphism, 50-64 probable polymorphism, 65-74 probably pathogenic mutation, >74 pathogenic 
mutation [27]. 
 
2.2.2.2 Provean (Protein Variation Effect Analyzer) 
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It is a web server which supports high-throughput analysis for human and mouse variants at both the 
genomic and protein levels and also provides accelerated analysis of protein variants from any organisms. If the 
PROVEAN score is equal to or below a pre-defined threshold (e.g. -2.5), the protein variant is predicted to have 
a "deleterious" effect otherwise the variant is predicted to have a "neutral" effect [28]. 
 
2.2.2.3 PolyPhen-2 (Polymorphism Phenotyping v2) 
The effect of a single-nucleotide change is predicted based on various features formulated from 
sequence annotations, multiple sequence alignments, and, where available, 3-D structures. PolyPhen-2 predicts 
change of a single nucleotide between numerical score ranging from 0.0 (benign) to 1.0 (damaging) [29]. 
  
2.3 Post Transcriptional Gene Silencing 
2.3.1 DESIGN OF siRNA 
Whitehead siRNA imbrute the design of short oligonucleotides twenty one nucleotide in length to 
prevent the expression of target genes. This tool uses various rules to design effective siRNAs such as 
thermodynamic stability of the double stranded RNA duplex, GC content, presence of SNPs [30]. 
 
2.3.2 Self-Complementary analysis of antisense strands 
2.3.2.1 RNAfold tool (http://rna.tbi.univie.ac.at/) 
Secondary structure can be predicted from a single sequence or the consensus for a set of aligned 
sequences using Vienna RNA secondary structure server. The server predicts minimum free energy (mfe) 
structure of a single sequence via classic algorithm of Zuker and Stiegler [31] and the centroid structure [32]. 
 
3. RESULTS AND ANALYSIS 
Alexander disease typically results from dominant mutations in gfap that arise de novo. Rosenthal 
fibers that are a prominent feature in AxD are formed due to accumulation of mutant glial fibrillary acidic 
protein (GFAP) [23]. Rosenthal fibers are also found to occur in some forms of cancer. Nam et al. (2015) has 
reported that most of the gfap mutations that have been identified in AxD are heterozygous, sporadic and 
missense mutations [33].  
To identify the validated variations that are known to cause the disease, the database OMIM was used. 
From the list of hits gene entry for Homo sapiens was selected having cytogenetic location -17q21.31 and the 
genomic coordinates- 17:44,905,625-44,915,551 [34]. The mutations causing the disease were explored using 
“Allelic Variants” option of OMIM and thirteen mutations in gfap (Table 1) were obtained. Therefore the 
present study was focused on these mutations. 
The pathogenicity of these 13 variations were analyzed using in silico mutation analysis tools PolyPhen 
2, UMD and Provean. For analysis in UMD predictor, multiple analyses were performed taking all the known 
mutations as the input. The tool allows the pathogenic assessment of the mutations using a combinatorial 
approach and gives results in a tabulated form where they are categorized according to the score that is 
generated (Table 1).  
 
Table 1.  Pathogenicity of gfap variants analyzed using various in silico tools 
S.No Substitution at 
nucleotide level 
Substitution at 
the amino acid 
level* 
PolyPhen Score UMD-predictor Score Provean score 
      
1. C>T R239C 1.000 99 -7.37 
2. G>A R239H 1.000 69 -4.60 
3. C>T R416W 0.997 100 -5.99 
4. G>A R79H 0.999 78 -4.84 
5. C>T R79C 0.466 96 -6.99 
6. C>T R88C 0.999 96 -7.40 
7. C>A R88S 0.978 96 -5.49 
8. C>T L76F 0.993 78 -3.86 
9. A>T N77Y 1.000 93 -7.73 
10. G>C E362D 1.000 69 -2.71 
11. G>T R276L 1.000 93 -6.51 
12. T>C L352P 1.000 87 -6.40 
13. C>A D78F 0.985 69 -3.87 
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The number of variants that were obtained from UMD predictor was 79, greater than the number of 
submitted variants due to the existence of variants in multiple transcripts. Out of these 62 were pathogenic, 11 
were probably pathogenic, 3 were polymorphism and 3 each showed polymorphism and probable 
polymorphism. 
The 13 pathogenic variations obtained from OMIM were also analyzed with two other in silico tools 
i.e. Provean and PolyPhen 2. The results obtained from all the in silico tools are tabulated in Table 1 to compare 
and assess the accuracy of prediction of mutations and shortlist the possible variants resulting in synthesis of 
mutant GFAP protein. The variations of gfap which are reported to be pathogenic in the OMIM databases were 
also found to be damaging or deleterious when analyzed using various in silico tools. 
Previous studies on the disease revealed that the mutations involving amino acid substitutions from 
arginine had the most common occurrence with a percentage of about 50.5% in the reported cases [35]. In the 
present study the mutations ARG239CYS (R239C), ARG416TRP (R416W), ARG88CYS (R88C) and 
ARG276LEU (R276L) were found to be most damaging and deleterious mutations. Nam et al have previously 
reported that ARG239CYS (R239C), ARG416TRP (R416W), ARG88CYS (R88C) and ARG276LEU (R276L) 
mutations occurring at nucleotide positions 729, 1246, 328 and 841[36-39] respectively are responsible for the 
pathophysiology of AxD and the formation of Rosenthal fibers thereby validating our observations. 
In the absence of any therapy/ commercially available drug for treatment of AxD or alleviation of its 
neuropathological feature of aggregation of Rosenthal Fibers, the present study was undertaken to prevent the 
expression of mutant gene, which may be targeted using Post Transcriptional Gene Silencing by design of 
siRNA constructs. 
siRNA were designed for the entire 13 gene mutations previously shortlisted using Whitehead siRNA 
web server and 10 constructs were obtained. As per siRNA design guidelines if GC content of one strand is 
greater than 60% it cannot become a functional siRNA because bond between guanine and cytosine are much 
stronger compared to A-U or A-T double bonds and each strand of siRNA can have a tendency to form loops by 
itself. Therefore, constructs C2, C3 and C4 were rejected as they form self-complimentary structures (Table 2) 
which may prevent the constructs from binding to their target mRNA and have effective PTGS role.  
For gene silencing those siRNAs can be effective which do not form secondary structure (internal 
hairpin and stem loops). Therefore, siRNA constructs C1, C5 and C6 were good candidates for gene silencing of 
gfap. Further the binding energy of constructs C1 and C6 were highly negative indicating highest specificity 
followed by C5 with nucleotide binding positions of 14-36, 1345-1367 and 1319-1341 in the gfap gene 
respectively.  
 
Table 2. siRNA secondary structures obtained using RNAfold server. 
No. Possible secondary structure (mfe) 
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In the present study, a computational biology approach has been used to target mutant gene gfap 
reported to be associated with AxD. siRNA were designed to prevent synthesis of mutant protein which results 
in formation of abnormal deposits known as Rosenthal Fibers. Three siRNA constructs designed in the present 
study i.e. C1, C6 and C5 which may be further tested for their efficacy in PTGS of mutant gfap to therapeutically 
alleviate symptoms of AxD by preventing the synthesis of mutant protein. 
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